Heart valve suit
This article was originally published in The Gray Sheet
Executive Summary
A news brief appearing in the Jan. 21, 2008, issue (1back cover) incorrectly stated that a patient death at issue in Blanco v. Baxter - a case decided by a California appeals court in favor of a heart valve device manufacturer that was sued for wrongful death - prompted a Class I recall of the device. In fact, the product recall occurred in 1988 and the patient death in question occurred in 2002
You may also be interested in...
Pre-emption prevails in California cases
California appellate courts rule in favor of FDA pre-emption of state tort liability claims involving PMA-approved devices in two separate cases Jan. 16 and Jan. 11. The case of Blanco v. Baxter, decided in California's fourth district, involved a patient who received a PMA-approved Baxter Edwards-Duromedics model 9120 mitral bileaflet heart valve and later died from a complication. In Jessen v. Mentor, decided in the second district, a plaintiff was implanted with a Mentor testicular prosthesis that had not been filled with saline prior to its implantation. Separately, a U.S. Supreme Court review of a PMA pre-emption case (Riegel v. Medtronic) remains ongoing (1"The Gray Sheet" Jan. 7, 2008, p. 10)
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.